| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $202,215 | 1 | 25 |
Sells | $2,670,901 | 3 | 75 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 1 | $202,215 | 0 | $0 | $202,215 |
| Hickey Benjamin | President, RayzeBio Org. | 0 | $0 | 1 | $3,702 | $-3,702 |
| Short Bartie Wendy | EVP, Corporate Affairs | 0 | $0 | 1 | $16,719 | $-16,719 |
| Elkins David V | EVP, Chief Financial Officer | 0 | $0 | 1 | $2.65M | $-2.65M |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Over the last 12 months, insiders at Bristol-Myers Squibb Company have bought $202,215 and sold $2.67M worth of Bristol-Myers Squibb Company stock.
On average, over the past 5 years, insiders at Bristol-Myers Squibb Company have bought $395,120 and sold $25.68M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) — $202,215.
The last purchase of 4,250 shares for transaction amount of $202,215 was made by Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) on 2025‑04‑25.
| 2025-09-02 | Sale | Elkins David V | EVP, Chief Financial Officer | 56,000 0.0027% | $47.33 | $2.65M | +9.48% | |
| 2025-08-02 | Sale | Short Bartie Wendy | EVP, Corporate Affairs | 378 <0.0001% | $44.23 | $16,719 | +3.66% | |
| 2025-05-09 | Sale | Hickey Benjamin | President, RayzeBio Org. | 97.39 <0.0001% | $38.01 | $3,702 | +3.74% | |
| 2025-04-25 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 4,250 0.0002% | $47.58 | $202,215 | +0.74% | ||
| 2025-02-20 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 2,000 <0.0001% | $55.05 | $110,096 | -11.79% | ||
| 2025-02-14 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 1,823.49 <0.0001% | $54.84 | $100,000 | -8.69% | ||
| 2024-11-04 | Sale | Holzer Phil M | SVP and Controller | 700 <0.0001% | $55.62 | $38,931 | -9.48% | |
| 2024-11-01 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 1,830 <0.0001% | $54.67 | $100,055 | -7.39% | ||
| 2023-12-05 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 2,000 <0.0001% | $49.78 | $99,560 | +1.35% | ||
| 2023-11-28 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 3,071 0.0002% | $48.86 | $150,049 | +3.88% | ||
| 2023-11-20 | Samuels Theodore R. II | director | 8,500 0.0004% | $49.81 | $423,385 | +3.56% | ||
| 2023-08-24 | Sale | Powell Ann | EVP, Chief Human Resources | 17,986 0.0009% | $61.25 | $1.1M | -16.48% | |
| 2023-08-03 | Sale | Plenge Robert M | EVP, Chief Research Officer | 732 <0.0001% | $61.14 | $44,754 | -16.03% | |
| 2023-05-03 | Sale | VESSEY RUPERT | EVP & President, Research | 50,385 0.0024% | $67.06 | $3.38M | -17.48% | |
| 2023-02-06 | Sale | Caforio Giovanni | Board Chair and CEO | 240,000 0.0115% | $74.65 | $17.92M | -15.58% | |
| 2023-02-06 | Sale | Powell Ann | EVP, Chief Human Resources | 11,183 0.0005% | $74.69 | $835,258 | -15.58% | |
| 2022-11-09 | Sale | Powell Ann | EVP, Chief Human Resources | 16,250 0.0008% | $80.45 | $1.31M | -15.71% | |
| 2022-11-07 | Sale | VESSEY RUPERT | EVP, Research & Early Dev. | 45,910 0.0022% | $78.88 | $3.62M | -14.61% | |
| 2022-09-20 | Sale | Caforio Giovanni | Board Chair and CEO | 25,000 0.0012% | $69.71 | $1.74M | +0.60% | |
| 2022-09-15 | Sale | Caforio Giovanni | Board Chair and CEO | 50,000 0.0023% | $71.84 | $3.59M | -2.21% |
| Elkins David V | EVP, Chief Financial Officer | 167379 0.0082% | $9.89M | 0 | 3 | |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 83513 0.0041% | $4.93M | 3 | 0 | <0.0001% |
| Short Bartie Wendy | EVP, Corporate Affairs | 5066 0.0002% | $299,299.28 | 0 | 1 | |
| Hickey Benjamin | President, RayzeBio Org. | 0 0% | $0 | 0 | 1 | |
| CELGENE CORP /DE/ | 10 percent owner | 7008510 0.3441% | $414.06M | 1 | 1 | +6.23% |
| ANDREOTTI LAMBERTO | director | 935571 0.0459% | $55.27M | 0 | 43 | |
| HOOPER ANTHONY C | SVP ComOps Pres USJap Int | 530806 0.0261% | $31.36M | 0 | 2 | |
| LEUNG SANDRA | EVP, General Counsel | 308627 0.0152% | $18.23M | 0 | 10 | |
| Cuss Francis M | EVP & CSO | 266033 0.0131% | $15.72M | 0 | 5 | |
| Caforio Giovanni | Board Chair and CEO | 236104 0.0116% | $13.95M | 0 | 19 | |
| Celentano John E | SVP HR Public Affairs & Philan | 213556 0.0105% | $12.62M | 0 | 5 | |
| Carlo de Notaristefani | Pres Tech Ops & Supp Fnctns | 197745 0.0097% | $11.68M | 0 | 4 | |
| Bancroft Charles A | EVP & Chief Financial Officer | 184694 0.0091% | $10.91M | 0 | 5 | |
| Cazala Beatrice J | EVP Commercial Operations | 173375 0.0085% | $10.24M | 0 | 5 | |
| SIGAL ELLIOT | EVP, CSO & President R&D | 148221 0.0073% | $8.76M | 1 | 10 | +21.5% |
| CORNELIUS JAMES M | director | 119464 0.0059% | $7.06M | 2 | 116 | +5.52% |
| BOERNER CHRISTOPHER S. | Chief Executive Officer | 104626 0.0051% | $6.18M | 3 | 1 | <0.0001% |
| von Autenried Paul | EVP, Chief Information Officer | 63536 0.0031% | $3.75M | 0 | 10 | |
| Elicker John E | EVP, Investor Relations | 58666 0.0029% | $3.47M | 0 | 9 | |
| ZABOR DAVID L | VP Strat Bus Initiatives | 54670 0.0027% | $3.23M | 0 | 1 | |
| DANIELS BRIAN | SVP Global Dev & Med Affairs | 53549 0.0026% | $3.16M | 0 | 7 | |
| Caldarella Joseph C | SVP & Controller | 46297 0.0023% | $2.74M | 0 | 15 | |
| VESSEY RUPERT | EVP & President, Research | 47751 0.0023% | $2.82M | 0 | 9 | |
| SKULE JOHN L III | SVP, Corp & Envirn Affairs | 39857 0.002% | $2.35M | 0 | 2 | |
| Samuels Theodore R. II | director | 35500 0.0017% | $2.1M | 5 | 0 | +7.16% |
| Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | 31956 0.0016% | $1.89M | 0 | 11 | |
| Moed Samuel J | SVP, Strat Plan & Analysis | 31015 0.0015% | $1.83M | 0 | 6 | |
| Powell Ann | EVP, Chief Human Resources | 27868 0.0014% | $1.65M | 0 | 5 | |
| Nielsen Anne | Chief Compliance & Ethics Off | 28126 0.0014% | $1.66M | 0 | 1 | |
| Zito Robert T | SVP & Chief Comm Officer | 24016 0.0012% | $1.42M | 0 | 1 | |
| MCBRIDE ANTHONY A | SVP Human Resources | 24637 0.0012% | $1.46M | 0 | 1 | |
| Huet Jean-Marc | EVP & CFO | 25000 0.0012% | $1.48M | 1 | 0 | +21.5% |
| Paliwal Dinesh C | director | 22109 0.0011% | $1.31M | 2 | 0 | +7.68% |
| Santiago Karen Murphy | SVP & Controller | 16704 0.0008% | $986,872.32 | 0 | 2 | |
| Dubow Adam | SVP,ChiefCompliance&EthicsOff. | 13777 0.0007% | $813,954.14 | 0 | 5 | |
| BERTOLINI ROBERT J | director | 11397 0.0006% | $673,334.76 | 1 | 0 | +34.5% |
| Holzer Phil M | SVP and Controller | 11760 0.0006% | $694,780.80 | 0 | 1 | |
| Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | 9251 0.0005% | $546,546.95 | 0 | 1 | |
| BONNEY MICHAEL W | director | 7189 0.0004% | $424,726.12 | 1 | 0 | +5.21% |
| Eid Joseph | SVP,Head Glob. Medical Affairs | 8069 0.0004% | $476,716.52 | 0 | 2 | |
| Plenge Robert M | EVP, Chief Research Officer | 6584 0.0003% | $388,982.72 | 0 | 1 | |
| FUTTER ELLEN V | director | 4894 0.0002% | $289,137.52 | 0 | 1 | |
| GROBSTEIN MICHAEL | director | 3383 0.0002% | $199,867.64 | 2 | 1 | +5.46% |
| LACY ALAN J | director | 2305 0.0001% | $136,179.40 | 0 | 1 | |
| CAMPBELL LEWIS B | director | 0 0% | $0 | 0 | 5 | |
| GLIMCHER LAURIE H M.D. | director | 0 0% | $0 | 0 | 2 |
$364,217,072 | 28 | 9.11% | $26.64B | |
$6,224,380 | 25 | 3.58% | $582.04B | |
$1,922,773,492 | 23 | 18.04% | $929.28B | |
Bristol-Myers Squibb Company (BMY) | $23,339,596 | 21 | 6.64% | $120.31B |
$28,542,809 | 19 | 26.39% | $388.43B | |
$2,523,290 | 18 | -0.87% | $151.25B | |
$17,274,470 | 17 | 3.96% | $285.86B | |
$356,328 | 15 | -42.83% | $70.73M | |
$3,170,734 | 10 | 3.98% | $197.41B | |
$3,933,798 | 8 | 12.50% | $179.99B | |
$252,679 | 2 | 0.47% | $1.65B | |
$8,176 | 1 | 13.73% | $50.67M |
| Increased Positions | 1,250 | +49.19% | 139M | +8.62% |
| Decreased Positions | 1,136 | -44.71% | 108M | -6.7% |
| New Positions | 353 | New | 28M | New |
| Sold Out Positions | 154 | Sold Out | 9M | Sold Out |
| Total Postitions | 2,655 | +4.49% | 2B | +1.92% |
| Vanguard Group Inc | $10.48M | 9.63% | 195.98M | +1M | +0.54% | 2025-09-30 |
| Blackrock, Inc. | $9.38M | 8.62% | 175.52M | +3M | +1.91% | 2025-09-30 |
| State Street Corp | $5.16M | 4.74% | 96.6M | +2M | +1.96% | 2025-09-30 |
| Jpmorgan Chase & Co | $4.61M | 4.23% | 86.18M | -18M | -17.1% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $3.9M | 3.59% | 73.04M | +2M | +3.16% | 2025-09-30 |
| Geode Capital Management, Llc | $2.49M | 2.29% | 46.55M | +377,610 | +0.82% | 2025-09-30 |
| Norges Bank | $1.79M | 1.65% | 33.57M | -2M | -4.55% | 2025-06-30 |
| Ameriprise Financial Inc | $1.74M | 1.6% | 32.47M | -105,784 | -0.33% | 2025-09-30 |
| Capital International Investors | $1.73M | 1.59% | 32.39M | -34M | -51.05% | 2025-09-30 |
| Morgan Stanley | $1.49M | 1.37% | 27.87M | +1M | +3.95% | 2025-09-30 |